Compare McCormick & Company, Incorporated (MKC) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McCormick & Company, Incorporated vs Zoetis Inc — how do they compare? McCormick & Company, Incorporated trades at $44.81 (market cap $12.39B), while Zoetis Inc trades at $74.77 (market cap $30.20B). The key difference: Zoetis Inc is far larger — about 2.4× McCormick & Company, Incorporated's market cap, and McCormick & Company, Incorporated pays the higher dividend (4.18%). Which is the better fit depends on your goals — on Pluang, investors hold McCormick & Company, Incorporated for 67 Days and Zoetis Inc for 70 Days on average.
| MKC | ZTS | |
|---|---|---|
Market Cap | $12.39B | $30.20B |
Volume | 6,140,872 | 6,175,327 |
Sector | Consumer Staples | Health |
52-Week High | $71.65 | $147.53 |
52-Week Low | $44.14 | $69.09 |
Typical Hold Time | 67 Days | 70 Days |
Enterprise Value | $17.07B | $37.76B |
Dividend Yield | 4.18% | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McCormick (MKC) trades at $44.81, down 0.97% on the day, with a bearish technical signal and neutral oscillators. The company reported strong Q3 2026 earnings, beating estimates with EPS of $0.86, driven by margin expansion and the McCormick de Mexico acquisition. Revenue grew 17% in constant currency, and the full-year outlook was reaffirmed. Valuation ratios appear attractive with a P/E of 8.31 and net income margin of 19.39%, while cash flow trends show improvement in 2026.
The outlook is mixed; fundamentals are solid with earnings beats and dividend growth, but technicals and analyst sentiment lean cautious. Upside exists if execution continues, yet risks include integration challenges and macroeconomic pressures. The consensus price target of $53.50 implies potential appreciation, but near-term volatility may persist.
Zoetis (ZTS) trades at $73.08, up 2.14% today, with a bullish technical signal but mixed earnings history including a recent Q1 2026 miss. The stock shows strong profitability with a 27.69% net income margin and 64.91% ROE, while valuation metrics like a P/E of 11.92 appear reasonable. Recent news highlights competitive pressures in the U.S. pet care market, though international segments remain resilient.
The outlook is cautiously optimistic; ZTS faces near-term headwinds from weak U.S. demand and competition, but its industry-leading margins and dominant market position support long-term growth. Risks include pricing erosion and guidance cuts, yet the consensus price target of $87.33 suggests upside potential for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About McCormick & Company, Incorporated
In its 130-year history, McCormick has grown to become the leading global manufacturer, marketer, and distributor of spices, herbs, extracts, seasonings, and other flavorings. Beyond end consumers, McCormick's customer base also includes top quick-service restaurants, retail grocery chains, and other packaged food and beverage manufacturers, with about 30% of sales generated beyond its home turf to include 150 other countries and territories. In addition to its namesake brand, the firm's portfolio includes Old Bay, Zatarain's, Thai Kitchen, Frank's RedHot, French's, and the recently acquired Cholula brand.
Read more on MKC →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
